Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSalÂ® ForspiroÂ® in Portugal and Ireland
Mar 11, 2015
Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
Innovative inhaler offers asthma and COPD patients a new therapeutic option
Now available to patients in 14 countries, as global roll-out continues apace
Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.
AirFluSal, which was first approved in Denmark, has now been launched in a dozen European countries, as well as South Korea and Mexico. It has been approved in more than two dozen countries and the planned global roll-out continues apace on a market-by-market basis, in line with local regulatory requirements.
“We are pleased to reach another milestone in our journey to make AirFluSal available to patients suffering from asthma and COPD,” said Jan-Torsten Tews, Head of Sandoz’s Global Respiratory Franchise. “This is an affordable and award winning new therapeutic option, developed in close collaboration with patients.”
AirFluSal offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. Safety, efficacy and equivalence have been proven in multiple clinical trials.
It was developed at Aeropharm GmbH in Rudolstadt, Germany, Sandoz’s global respiratory Center of Excellence. Sandoz collaborated with UK-based Vectura, a respiratory product development company, in the design and development. The innovative and intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.
In order to improve patient experience with inhalation devices, Sandoz collaborated closely with patients during the development process. The device includes multiple feedback mechanisms such as visual control features, which help reassure the patient about dosing and a simple lever arm to load the dose.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. In addition, Sandoz holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal. Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products – products that are scientifically more difficult to develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).